These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 26362702)

  • 1. Risk factors for cardiovascular disease in rheumatoid arthritis patients from Mato Grosso do Sul.
    de Deus Junior RS; Ferraz AL; Oesterreich SA; Schmitz WO; Shinzato MM
    Rev Bras Reumatol; 2015; 55(6):493-500. PubMed ID: 26362702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticyclic Citrullinated Peptide Antibodies and Rheumatoid Factor as Risk Factors for 10-year Cardiovascular Morbidity in Patients with Rheumatoid Arthritis: A Large Inception Cohort Study.
    Berendsen MLT; van Maaren MC; Arts EEA; den Broeder AA; Popa CD; Fransen J
    J Rheumatol; 2017 Sep; 44(9):1325-1330. PubMed ID: 28668802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overlap between systemic sclerosis and rheumatoid arthritis: a distinct clinical entity?
    Horimoto AM; da Costa IP
    Rev Bras Reumatol Engl Ed; 2016; 56(4):287-98. PubMed ID: 27476621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High density lipoprotein in rheumatoid arthritis: emerging role in predicting inflammation level and osteoporosis occurrence.
    Zeng T; Tan L; Yu J; Wu Y
    Scand J Clin Lab Invest; 2020 Sep; 80(5):375-380. PubMed ID: 32279574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA-DRB1 shared epitope alleles in patients with rheumatoid arthritis: relation to autoantibodies and disease severity in a south Indian population.
    Konda Mohan V; Ganesan N; Gopalakrishnan R; Venkatesan V
    Int J Rheum Dis; 2017 Oct; 20(10):1492-1498. PubMed ID: 27943654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular risk in persons at risk of developing rheumatoid arthritis.
    van Boheemen L; van Beers-Tas MH; Kroese JM; van de Stadt LA; van Schaardenburg D; Nurmohamed MT
    PLoS One; 2020; 15(8):e0237072. PubMed ID: 32745151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease Activity, Oxidized-LDL Fraction and Anti-Oxidized LDL Antibodies Influence Cardiovascular Risk in Rheumatoid Arthritis.
    Nowak B; Madej M; Łuczak A; Małecki R; Wiland P
    Adv Clin Exp Med; 2016; 25(1):43-50. PubMed ID: 26935497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study.
    Takeuchi T; Miyasaka N; Inui T; Yano T; Yoshinari T; Abe T; Koike T
    Arthritis Res Ther; 2017 Sep; 19(1):194. PubMed ID: 28865493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study.
    Ajeganova S; Andersson ML; Frostegård J; Hafström I
    J Rheumatol; 2013 Dec; 40(12):1958-66. PubMed ID: 23950188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive.
    Hiwa R; Ohmura K; Nakabo S; Terao C; Murakami K; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Hashimoto M; Furu M; Ito H; Fujii T; Mimori T
    Int J Rheum Dis; 2017 Jun; 20(6):731-736. PubMed ID: 28198158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study.
    Alemao E; Guo Z; Frits ML; Iannaccone CK; Shadick NA; Weinblatt ME
    Semin Arthritis Rheum; 2018 Apr; 47(5):630-638. PubMed ID: 29241640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
    de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
    Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follicular helper T cells in peripheral blood of patients with rheumatoid arthritis.
    Costantino AB; Acosta CDV; Onetti L; Mussano E; Cadile II; Ferrero PV
    Reumatol Clin; 2017; 13(6):338-343. PubMed ID: 27595364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness.
    del Val del Amo N; Ibanez Bosch R; Fito Manteca C; Gutierrez Polo R; Loza Cortina E
    Clin Exp Rheumatol; 2006; 24(3):281-6. PubMed ID: 16870095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 and IgA-rheumatoid factor are crucial for baseline erosiveness, and anti-citrullinated peptide antibodies for radiographic progression in early rheumatoid arthritis treated according to a treat-to-target strategy.
    Fedele AL; Petricca L; Tolusso B; Alivernini S; Canestri S; Di Mario C; Bosello SL; Ferraccioli G; Gremese E
    Scand J Rheumatol; 2018 Sep; 47(5):351-359. PubMed ID: 29542372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CCP2 is an adjunct to, not a surrogate for, rheumatoid factor in the diagnosis of rheumatoid arthritis: diagnostic utility of anti-CCP2 antibodies in Egyptian patients with rheumatoid arthritis.
    Abdel-Nasser AM; Mahmoud MH; El Mansoury TM; Osman AM
    Scand J Rheumatol; 2008; 37(5):329-36. PubMed ID: 18666028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis.
    Ahmadi H; Jamshidi AR; Mahmoudi M; Cuzzocrea S; Fattahi MJ; Barati A; Rehm BHA; Matsuo H; Mirshafiey A
    Curr Drug Discov Technol; 2017; 14(3):206-214. PubMed ID: 28325148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA.
    Hecht C; Englbrecht M; Rech J; Schmidt S; Araujo E; Engelke K; Finzel S; Schett G
    Ann Rheum Dis; 2015 Dec; 74(12):2151-6. PubMed ID: 25115448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study.
    Bird P; Nicholls D; Barrett R; de Jager J; Griffiths H; Roberts L; Tymms K; McCloud P; Littlejohn G;
    Int J Rheum Dis; 2017 Apr; 20(4):460-468. PubMed ID: 28205333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.